Short Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Declines By 66.2%

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 1,650 shares, a decline of 66.2% from the February 12th total of 4,878 shares. Based on an average trading volume of 15,596 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 15,596 shares, the short-interest ratio is currently 0.1 days.

NRx Pharmaceuticals Stock Up 26.5%

Shares of NRXPW stock traded up $0.01 on Friday, reaching $0.03. The company had a trading volume of 17,404 shares, compared to its average volume of 21,269. The business’s 50-day moving average is $0.05 and its 200 day moving average is $0.08. NRx Pharmaceuticals has a one year low of $0.01 and a one year high of $0.18.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.

Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.